Intuitive Surgical Finally Prices the Pivot: A 3-5% Haircut to Buy Volume
The number Jamie Samath deferred in July arrived Tuesday — and it lands on top of the lowest US da Vinci procedure growth since COVID, a $450M remanufacturing settlement, and a stock still 28% below its peak.
ISRG · Earnings Call · 2026-10-20
The number management would not give in July
Three months ago, Jamie Samath was asked point-blank to size the extended-use pricing program. He demurred: “Not ready to quantify it yet... we will do that on the next earnings call.” — Jamie E. Samath, Chief Financial Officer · 2026-07-16 On Tuesday he did.
We expect to reduce da Vinci I&A revenue per procedure by approximately 3% to 5% on a mix-constant basis once fully implemented.
The mechanics: extend the useful life of a subset of core endo wrist instruments on the fourth- and fifth-generation platforms, layer in volume-based pricing, and absorb a China charge-code price reduction that begins in November. It is aimed squarely at high-volume benign work — cholecystectomy, inguinal hernia repair — where cost, not capability, is the gating factor. These are pricing actions with a strategic purpose, not a defensive concession, and management was careful to note the hit is smaller than the 7% they booked when they launched the first extended-use program in 2020.
David Rosa framed it as arithmetic, not retreat: “It is not a trade-off. It is our strategy to really expand our addressable market and serve more patients around the globe.” — Dave Rosa, Chief Executive Officer · 2026-10-20 That framing is not new — in April, Samath described a push-pull where Intuitive shares cost savings with cost-sensitive segments precisely to capture elasticity. What is new is the price tag on the strategy. This quarter converted philosophy into a disclosed revenue-per-procedure headwind, and that is the single most important thing that changed at this company.
Why now: a deceleration nobody tried to spin
US da Vinci procedure growth was 10% against 20% outside the US. Larry Biegelsen said the quiet part:
The 10% growth in the quarter was the lowest we have seen since COVID.
Management did not argue. Instead it re-listed the four levers it has been building toward: capacity, ambulatory surgery, cardiac and breast, and R&D-driven indications. Capital is emphatically not the constraint — 546 da Vinci systems placed, up 28%, net placements up 40%, US net placements up 41%, 315 da Vinci 5 units, and 65 XiR at roughly $1.2 million against 37 X systems at about $500,000. Revenue rose 22% to just over $3 billion with 84% recurring. The ASC opportunity is the newest leg, now served by a tiered portfolio and, per Samath, still under 10% of US soft tissue volume.
What the tape says is different from what the P&L says. The shares sit 28.2% below the January 2025 peak of $610.45, yet have recovered 6.3% over the last 90 trading days. The de-rating has been about multiple, not earnings: price-to-revenue sits at 12.8x, down 40% year over year. Even after that, at 44.6x trailing net income, the market is not paying for a value stock.
Buried under the pricing news was the other structural event: a $450 million no-fault settlement with US customers over third-party instrument remanufacturing and system servicing, subject to court approval. GAAP EPS fell to $1.49 from $1.95. The irony is thick — Intuitive settled with the remanufacturers, then decided to extend instrument life and lower price itself. It removes a nagging overhang on the instrument annuity, which was always the real asset.
The offsets are real, but one is conspicuously small
Analysts pressed for what fills the 3-5% hole. Samath offered three: SP instrument revenue per procedure runs above multi-port, da Vinci 5 integrated insufflation adds roughly $100 per procedure on about 85% of cases, and force feedback. The last one is the tell. Adam Maeder asked directly, and the answer was: “About 8% of da Vinci 5 cases involve force feedback.” — Jamie Samath, Chief Financial Officer · 2026-10-20 Supply only normalized late in the quarter, and the company says its ambitions are much higher — but the highest-value clinical differentiator it owns is penetrative at single digits. If the price cut is the cost, force feedback adoption is the thing that has to scale to pay for it.
Margins give them room. Non-GAAP operating margin was 42%, or 41% excluding a $28 million IEEPA tariff refund — above the 35-40% band management has cited for years. The read-through for 2027 is not what a bull wants: “Where we are right now, 41-42%, we have the capacity to invest.” — Jamie Samath, Chief Financial Officer · 2026-10-20 Translation: the margin upside is earmarked for R&D, which already runs hot — R&D was 12.8% of revenue in the latest filed quarter.
The theme that quietly vanished
The most interesting absence on this call is bariatrics. For six quarters the drag was a fixture — “Domestic bariatric procedures continue to decline at high single digits” — Dan Connolly, Vice President, Investor Relations · 2025-10-21 — complete with GLP-1 debates and surgeon roundtables. On Tuesday it was not mentioned once. Neither was GLP-1. The ACA subsidy question, which dominated July, was demoted to a single clause in the guidance range. When a company stops discussing its own headwind, it usually means the headwind has stopped being interesting.
What replaced it is benign general surgery, reinforced by a 1.5-million-patient Benign COMPARE meta-analysis showing 54% lower odds of conversion to open surgery versus laparoscopy — the clinical evidence that has to underwrite a price cut aimed at laparoscopy, not at other robots. Cardiac procedures grew 40% with a line-of-sight opportunity of 300,000-400,000 procedures a year in cleared regions, and breast surgery grew 42%. Both are small today and training-gated. The global keyword set confirms the benign-hernia wave is not an Intuitive invention — Inguinal hernia repair ranked high across the whole market this quarter.
On competition, Rick Wise asked whether new modular systems in the ASC force a hardware answer. Rosa did not blink: “We continue to believe that a cart-based architecture consistent with da Vinci is the best option.” — Dave Rosa, Chief Executive Officer · 2026-10-20 The response was economics, not engineering. That is the whole quarter in miniature: Intuitive is competing on cost of ownership and ecosystem breadth rather than on a new robot.
The bet, stated plainly
Intuitive gave up 3-5% of instrument revenue per procedure in exchange for volume in the procedures where the alternative is a laparoscope, not a competitor. Management has one data point supporting the elasticity thesis — the 2020 program — and one quarter of evidence that the US procedure base is slowing. If benign general surgery inflects through 2027 and 2028, this looks like the moment a premium-priced platform became a volume platform. If it does not, the company has cut price into a decelerating market and invited a margin debate it spent a decade avoiding. Either way, the story is no longer about whether demand exists. It is about what Intuitive is willing to charge for it.